Cycle on Jun 24, 2026

I will start by listing the open threads and watches for this topic using the `list_threads` tool to see what needs to be prioritized or checked for updates.

I will search for any recent news regarding Amgen and Tavneos, especially concerning the Duke Clinical Research Institute (DCRI) independent re-evaluation or the FDA's proposed withdrawal, since the docket is scheduled to close soon (June 29, 2026).

I will search for any other recent, high-impact clinical trial readouts or FDA approvals from the last few weeks in June 2026. Let's do some general searches for FDA approvals and phase 3 clinical trials.

Wow, very interesting! 1. Trodelvy (sacituzumab govitecan) + Keytruda (pembrolizumab) or Trodelvy alone approved as first-line therapy for unresectable/metastatic triple-negative breast cancer (TNBC) on June 24, 2026. 2. Pfizer's Ibrance (palbociclib) combo approved for HR+, HER2+ metastatic breast cancer frontline maintenance on June 24, 2026 (based on the PATINA trial). 3. FDA revised draft guidance on June 22, 2026 on master protocols. 4. Let's look up the Merck approvals as well. Let's fetch the Trodelvy first-line TNBC approval and the Pfizer Ibrance PATINA approval to get accurate details and quotes. First, let's search specifically for Trodelvy's FDA approval on June 24, 2026.

Let's fetch the Endpoints News article or Fierce Pharma article to get the full story on Trodelvy's frontline TNBC approval, which occurred on June 24, 2026. This is a massive development in oncology! I'll choose the Fierce Pharma link. Let's do a fetch. Oh, wait, let's fetch `https://www.fiercepharma.com/pharma/gilead-trodelvy-nabs-broad-fda-approval-front-line-tnbc-fueling-trop2-adc-market-war` or `https://firstwordpharma.com/story/7647143`. Let's search for the exact URL or use the businesswire one since it's the official press release. Let's do a web fetch on the BusinessWire or Fierce Pharma URL. Let's try the Fierce Pharma URL. Wait, is the Fierce Pharma URL available? Yes, the URL is: `https://www.fiercepharma.com/pharma/gilead-trodelvy-nabs-broad-fda-approval-front-line-tnbc-fueling-trop2-adc-market-war` Let's fetch it. Oh, let's also search for the BusinessWire URL or the Gilead press release. Let's try to fetch Fierce Pharma first.

This is an incredible development: - **Gilead's Trodelvy (sacituzumab govitecan-hziy)** was approved by the FDA on June 24, 2026 for **first-line metastatic triple-negative breast cancer (TNBC)**. - It was approved in two distinct indications: 1. As a monotherapy for patients who are not candidates for PD-1/PD-L1 inhibitors (backed by Phase 3 **ASCENT-03** trial showing a 38% reduction in the risk of disease progression or death vs chemotherapy). 2. In combination with Merck's **Keytruda (pembrolizumab)** for patients with PD-L1-positive tumors (CPS >= 10), backed by Phase 3 **ASCENT-04** (also known as Keynote-D19), which showed a 35% improvement in PFS vs Keytruda and chemotherapy. - This creates a massive market showdown with **Daiichi Sankyo and AstraZeneca's Datroway (datopotamab deruxtecan)**, which received a narrower FDA approval for front-line TNBC patients ineligible for PD-1/L1 inhibitors just a month earlier (based on the Tropion-Breast02 trial). - There is also **Kelun-Biotech's sac-TMT** (partnered with Merck outside China) which is a strong competitor. Let's write a note about this major oncology development. But wait, let's also look into Pfizer's Ibrance PATINA trial approval to see if we should write a separate note or combine/expand. Remember the rule: "One finding = ONE coherent subject tracked under one stable slug across cycles... NEVER write a note that summarizes the cycle, bundles several unrelated subjects into one write-up". So they should be separate notes. Let's check the Pfizer Ibrance PATINA approval details. Let's do a web search.

Let's fetch the Fierce Pharma article on Ibrance's expansion to get details and verbatim quotes. It's titled "Pfizer scores 1st expansion in 7 years for breast cancer blockbuster Ibrance". Let's fetch it.

This is another major development! Let's write notes for both of these massive oncology approvals. Wait, are there any other major updates? Let's look at the "Amgen Tavneos FDA hearing submission and public docket close" watch. The watch says: "Monitor Amgen's submission of the Duke Clinical Research Institute (DCRI) independent re-evaluation of the ADVOCATE trial data and the close of the FDA public comment period on the proposed withdrawal of Tavneos. Fires when Amgen submits its evidence and the public docket closes on June 29, 2026." Wait, the date is June 24, 2026. The docket hasn't closed yet (it closes on June 29, 2026). Let's double check if there's any new information or if we should record an event or update the prior note `amgen-tavneos-fda-scrutiny-withdrawal-dispute`. Wait, let's search for "Amgen Tavneos Duke ADVOCATE" to see if Amgen has already submitted the DCRI independent re-evaluation. Let's do a search. We saw several articles from "2 weeks ago" (which would be around June 10–11, 2026) saying "Amgen shores up Tavneos’ FDA defense with Duke data analysis". Let's fetch one of those articles to see what the Duke analysis actually found and what was submitted. Let's fetch the Fierce Pharma article from 2 weeks ago about this: `https://www.fiercepharma.com/pharma/fda-hearing-on-Amgen's-Tavneos-will-include-findings-independent-review` or let's search for it. Let's do a quick search.

Let's fetch the BioSpace article `https://www.biospace.com/business/amgen-shores-up-tavneos-fda-defense-with-duke-data-analysis` to see what details are provided. This is very relevant to our prior finding `amgen-tavneos-fda-scrutiny-withdrawal-dispute`. Let's fetch it.

Excellent. So the Duke Clinical Research Institute (DCRI) re-adjudication was commissioned by Amgen to review the ADVOCATE trial's primary endpoints (which began in February 2026), and Amgen plans to submit the results along with other detailed data to the FDA by June 29, 2026. This is exactly the date of the public docket closing. Let's update the prior finding `amgen-tavneos-fda-scrutiny-withdrawal-dispute` to reflect these major updates (the Duke Independent Re-evaluation details, the June 29 submission deadline, and the European Medicines Agency review and Kissei Pharmaceutical deaths in Japan). Let's check if there are other watches we should investigate. What about MoonLake's sonelokimab in psoriatic arthritis (Phase 3 IZAR-1 trial) or hidradenitis suppurativa BLA? Let's search for "MoonLake sonelokimab" to see if there are any recent updates. MoonLake has been expected to read out Phase 3 IZAR-1 in mid-2026 and submit the BLA in late September 2026. Let's run a search.

Ah! Let's search for "MoonLake sonelokimab Week 52 Phase 3 VELA results" or "MoonLake sonelokimab IZAR-1". Let's do a search for "MoonLake sonelokimab VELA" to see what has happened in the last week. This is extremely recent (3 days ago - June 21/22, 2026)! Let's do a search.

This is a major clinical trial readout update! Let's fetch the article from Clinical Trial Vanguard: `https://www.clinicaltrialvanguard.com/news/moonlakes-sonelokimab-achieves-67-hiscr75-response-in-phase-3-hs-trial/` or look for the official press release on MoonLake's website. Let's do a search for the Yahoo Finance or BusinessWire press release for MoonLake's Week 52 Phase 3 VELA results in June 2026.

This is incredibly high-quality data! Let's fetch the GlobeNewswire press release (`https://www.globenewswire.com/news-release/2026/06/21/3314997/0/en/moonlake-announces-week-52-results-of-sonelokimab-from-its-phase-3-vela-program-in-hidradenitis-suppurativa-and-confirms-investor-day-on-june-22-2026.html`) or the StockTitan 8-K filing summary. Let's do a fetch of GlobeNewswire.

This is a huge, highly relevant update for MoonLake's sonelokimab. Let's review what we have: 1. **MoonLake's Sonelokimab 52-Week Phase 3 VELA Results in HS**: - Released June 21, 2026. - VELA-1 and VELA-2 trials (n=396): 67.2% of patients achieved HiSCR75 at Week 52, 33.1% achieved HiSCR100, and 26.0% achieved IHS4-100 (inflammatory remission). - Showed a potential best-in-class / best-in-disease profile, outperforming previous Phase 3 results of competitors (such as UCB's Bimzelx/bimekizumab, which is an IL-17A & F inhibitor). - VELA-TEEN adolescent data (n=22) showed ~68% achieved HiSCR75 and ~45% achieved HiSCR100 at Week 24. - BLA submission for HS is planned for the end of September 2026, with a PDUFA date allocation expected by late November 2026. They will request Priority Review. - This directly updates the thread/watch: `MoonLake BLA submission for sonelokimab in Hidradenitis Suppurativa` (ID: `019ef183-efef-70f6-9f55-cbbd11c943bb`) and `MoonLake Phase 3 IZAR-1 trial readout of sonelokimab in psoriatic arthritis` (ID: `019ef184-1ea4-72e1-a12e-ed934bbac64e`). - We should write a finding note tracking this. Wait, are there other recent developments we should check? What about: - **Belite Bio's tinlarebant (LBS-008)**: Completed rolling NDA on June 12, 2026. Is there any new update? The 60-day review period is ongoing (expected early August 2026). Let's search just in case there is anything new. - **HHS launches Operation Trialblazer**: Let's see if there are any new updates on Operation Trialblazer. Let's do a quick search. - **Disc Medicine's bitopertin in EPP**: Let's see if there is any new update on Disc Medicine or GondolaBio. - **Modern's mFlusiva (mRNA-1010)**: PDUFA date is August 5, 2026. Let's check if there are any recent updates. - **ISS Russian Zvezda module air leaks**: Let's do a quick search on ISS air leaks to see if there's any recent news from June 2026. - **Ebola vaccines / Bundibugyo Ebola vaccines**: Let's check if there are any recent updates. - **USDA's sterile fly facility in Texas**: Let's search if there's any new news. Let's do some searches. First, let's search for "Operation Trialblazer HHS clinical trials" to see if there are any updates.

Whoa! This is a massive update on Operation Trialblazer/Trailblazer! Wait, the prior finding had the slug `hhs-clinical-trials-reform-operation-trialblazer` and the title was "HHS Launches 'Operation Trialblazer' to Sweepingly Reform US Clinical Trials and Counter China". Wait, the news is that on **June 22, 2026**, HHS and Secretary Robert F. Kennedy, Jr. formally launched **Operation Trailblazer** (note: it's spelled "Trailblazer" in some places, "Trialblazer" in others, but the official name appears to be **Operation Trailblazer** or **Operation Trialblazer**, let's see. The headlines say "Operation Trailblazer Launches to Restore U.S. Leadership to Clinical Trials" and "HHS Secretary Robert F. Kennedy, Jr. launches Operation Trialblazer"). Let's fetch the Regulatory Affairs Professionals Society (RAPS) page or the BioWorld page or the HIT Consultant page to get the exact details. Let's fetch RAPS first: `https://www.raps.org/resource/hhs-and-fda-propose-clinical-trial-reforms-to-expedite-drug-development.html` or the HIT Consultant article `https://hitconsultant.net/2026/06/22/hhs-launches-operation-trialblazer-clinical-trials/`. Let's do a fetch of the RAPS article.

This is an absolutely phenomenal update on **Operation Trailblazer** (with some documents using "Trailblazer" and others "Trialblazer", let's make sure we note both). Let's see: - On **June 22, 2026**, HHS Secretary Robert F. Kennedy, Jr. and the FDA formally launched **Operation Trailblazer** (also referenced as **Operation Trialblazer**). - Key initiatives include: 1. A proposal for the **Expedited Investigational New Drug (IND) pilot program**, which allows pharmaceutical companies to partner with qualified external research institutions (academic medical centers or contract research organizations) to develop Phase 1 IND submissions for first-in-human (FIH) trials using a rolling IND submission platform to minimize clinical holds. 2. A revised **draft guidance** entitled *"Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products"*, clarifying when drug developers can rely on **one rigorous, adequate, and well-controlled pivotal clinical trial plus confirmatory evidence** instead of the traditional two trials. 3. A new draft guidance on **Quantitative Systems Pharmacology (QSP)** to help determine the minimum anticipated biological effect level (MABEL) dose in first-in-human Phase 1 trials, moving away from historical animal-toxicology-based dose-selection methods. 4. Updated draft guidance on **master protocols** (basket, umbrella, and platform trials). 5. The launch of **"The Phase 1 IND Navigator"** webpage and a dedicated Phase 1 call center to answer real-time questions. 6. Clarifications on Chemistry, Manufacturing, and Control (CMC) requirements to prevent companies from submitting excessive and unnecessary data at the Phase 1 stage. This is a massive development that directly updates the prior finding `hhs-clinical-trials-reform-operation-trialblazer`. Let's update `hhs-clinical-trials-reform-operation-trialblazer` using the `write_note` tool. Wait, let's also search for updates on the ISS Russian Zvezda module air leaks. Let's do a search.

Wow, this is an incredible, highly dramatic development on the ISS. Let's see what happened: - On **June 5, 2026**, the air leak in the Russian Zvezda module's transfer chamber (PrK) worsened significantly, leading NASA to order an emergency shelter-in-place for five US orbital segment astronauts. They had to retreat to the docked SpaceX Crew Dragon capsule while Russian cosmonauts performed emergency repairs on the module. - On **June 8, 2026**, NASA provided an update stating that the leak rate had increased, and they are investigating new microscopic cracks. - A risky structural repair plan was put on hold because engineers feared it might compromise the structural integrity of the module further. - By **June 18, 2026**, reports emerged of a growing dispute between NASA and Roscosmos. Russia is likely to halt major repairs on the leaking PrK transfer tunnel entirely and keep the hatch closed permanently. If they keep the hatch closed permanently, it means they would lose access to the Progress cargo spacecraft docking port at the end of the Zvezda module (which is critical for cargo delivery and orbit-raising burns). - This is a major update that directly fires the watch: `ISS Russian Zvezda module air leaks and repairs` (ID: `019ea447-7d90-733c-acee-2eb6c1313c78`). Let's fetch the Gizmodo article from June 18, 2026, or the TS2/Hackaday article to get precise quotes and a deep understanding. Let's do a search for the Gizmodo article `Russia Might Be Ready to Give Up on Its Leaky ISS Module` or fetch `https://gizmodo.com/russia-might-be-ready-to-give-up-on-leaky-iss-module-2000773240` or search for its details. Let's try to fetch it. Wait, let's search first for "Russia Might Be Ready to Give Up on Its Leaky ISS Module" to get the exact URL or text, or we can fetch `https://gizmodo.com/russia-might-be-ready-to-give-up-on-leaky-iss-module-2000773240`. Let's try fetching Gizmodo.

This is an incredible, detailed article with exactly the kind of primary evidence and quotes we need. Let's analyze this: - **ISS Air Leak Saga Worsens**: - Since 2019, a persistent air leak has existed in the PrK (transfer chamber/vestibule) of the Russian Zvezda service module. - On **June 5, 2026**, the situation escalated when NASA ordered five astronauts to shelter in place inside the SpaceX Crew Dragon capsule while Roscosmos cosmonauts prepared to attempt a highly risky structural repair: using a saw to cut away a load-bearing bracket to gain better access to the crack. - NASA strongly opposed this saw-cutting plan, warning it "could have resulted in elevated risk to the structure in the area." - Following the standoff and NASA's emergency shelter-in-place order, Roscosmos backed down and postponed the operation. - According to subsequent reports in mid-June 2026, Russia has now informed NASA that it will throw in the towel and decommission the PrK vestibule altogether. - This involves permanently closing the hatch to isolate the leaky chamber from the rest of the station, which will end the leak but permanently cut off access to that specific docking port (meaning Russian cosmonauts can no longer use it for cargo/supplies or orbit-raising burns). - This is an ongoing watch, so we should call `record_event` on the thread `ISS Russian Zvezda module air leaks and repairs` (ID: `019ea447-7d90-733c-acee-2eb6c1313c78`), but set `resolves: false` as we'll want to continue monitoring the actual sealing and final decommissioning of the hatch. Wait, let's write three notes first: 1. One for **Gilead's Trodelvy broad FDA approval in first-line metastatic TNBC** (June 24, 2026). Let's think about the slug. The topic brief asks us to track consequential science and health. Let's make the slug: `gilead-trodelvy-fda-approval-first-line-tnbc`. 2. One for **Pfizer's Ibrance FDA expansion in HR+/HER2+ metastatic breast cancer maintenance** (June 24, 2026). Let's make the slug: `pfizer-ibrance-fda-approval-hr-her2-breast-cancer`. 3. One for **MoonLake's Sonelokimab Phase 3 VELA Week 52 Results in HS** (June 21, 2026). Wait, let's check if there is an existing slug or prior finding for MoonLake. The prior findings are: - `hhs-clinical-trials-reform-operation-trialblazer` - `belite-bio-tinlarebant-stargardt-disease-nda` - `disc-medicine-bitopertin-epp-crl-path` - `grail-nhs-galleri-mced-trial-results` - `amgen-tavneos-fda-scrutiny-withdrawal-dispute` No prior finding for MoonLake, but we have two watches for MoonLake: - `MoonLake BLA submission for sonelokimab in Hidradenitis Suppurativa` (ID: `019ef183-efef-70f6-9f55-cbbd11c943bb`) - `MoonLake Phase 3 IZAR-1 trial readout of sonelokimab in psoriatic arthritis` (ID: `019ef184-1ea4-72e1-a12e-ed934bbac64e`) Let's create a new note with slug: `moonlake-sonelokimab-phase3-vela-hidradenitis-suppurativa`. And we will update the following existing findings: - `hhs-clinical-trials-reform-operation-trialblazer` (using the formal launch of Operation Trailblazer on June 22, 2026, and the 1-trial draft guidance, pilot program, etc.). - `amgen-tavneos-fda-scrutiny-withdrawal-dispute` (using the Duke Clinical Research Institute independent re-evaluation details, Japan deaths, EMA review, and the June 29 deadline). Wait, let's check if there are other watches that we can resolve or record events on. Let's see: - `Amgen Tavneos FDA hearing submission and public docket close` (ID: `019ec855-5381-7936-a3b6-a40d207e679d`): This is a dated catalyst for June 29, 2026. The current date is June 24, 2026. Amgen has already announced they will submit the Duke re-evaluation data by June 29, 2026. Let's record an event on it to note that Amgen has engaged Duke and plans to submit by June 29, but let's keep it open or wait until the next cycle to resolve it when the actual submission happens and the docket closes on June 29, or we can record it now. Let's keep it open for now or see if we should record an event. - `MoonLake BLA submission for sonelokimab in Hidradenitis Suppurativa` (ID: `019ef183-efef-70f6-9f55-cbbd11c943bb`): This has a fire date of September 30, 2026. The VELA results just came out, confirming the BLA submission is expected in late September 2026. This watch is still in the future, so it hasn't fired yet. - `ISS Russian Zvezda module air leaks and repairs` (ID: `019ea447-7d90-733c-acee-2eb6c1313c78`): This has fired because a major leak escalation occurred on June 5, 2026, leading to a shelter-in-place and Russia deciding to decommission the PrK module in mid-June. This is an ongoing watch, so we can record an event on it and keep it open (`resolves: false`). Let's write the notes first. ### Note 1: `gilead-trodelvy-fda-approval-first-line-tnbc` Let's write a note about Gilead's Trodelvy approval. Wait, let's double check if we need any other sources. The Fierce Pharma article is excellent and has great quotes. Let's verify the quotes: "Less than a month after an approval for Daiichi Sankyo and AstraZeneca’s Datroway for front-line TNBC patients who are not candidates for PD-1/L1 inhibitors, the FDA has handed Gilead Sciences’ Trodelvy a rivaling approval that allows the drug to be used regardless of patients’ PD-L1 status." "The new FDA approval for Trodelvy in first-line TNBC now allows the first-in-class TROP2 ADC to be used either alone for patients who aren’t eligible for PD-1/L1 inhibitors or in combination with Merck & Co.’s Keytruda for those with PD-L1-positive tumors, defined as a combined positive score of at least 10." Let's write this note. Let's state intent. I will write the finding for Gilead's Trodelvy approval.

Now I will write a finding note for Pfizer's Ibrance FDA expansion in HR+/HER2+ metastatic breast cancer maintenance on June 24, 2026. Let's verify the quotes and details: "On Wednesday, the FDA gave the CDK4/6 inhibitor a shot in the arm, signing off on Ibrance as a maintenance option for patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer after induction treatment." "With today’s FDA approval, Ibrance becomes the first and only CDK4/6 inhibitor indicated for patients with HR+ metastatic breast cancer regardless of HER2 status, extending its impact to patients who continue to face challenges with treatment resistance," Aamir Malik, Pfizer's U.S. commercial chief, said in a Jun. 24 statement." "Paving the way for the expansion were results from the phase 3 Patina study, which showed that Ibrance added to standard of care reduced the risk of disease progression or death by 24% in the specific patient population following induction treatment, Pfizer said in a Wednesday press release. The Ibrance combo also extended the median progression-free survival time of patients by 15.2 months to 44.3 months." Let's write this note. Let's state intent. I will write the finding for Pfizer's Ibrance approval.

Now I will write a finding note for MoonLake's sonelokimab Phase 3 VELA results in moderate-to-severe hidradenitis suppurativa (HS) released on June 21, 2026. Let's verify the details and quotes: - VELA-1 and VELA-2 trials (n=396): 67.2% achieved HiSCR75 at Week 52, 33.1% achieved HiSCR100, and 26.0% achieved IHS4-100 (inflammatory remission). - VELA-TEEN trial (n=22): ~68% achieved HiSCR75 and ~45% achieved HiSCR100 at Week 24. - BLA submission expected at the end of September 2026. - PDUFA date allocation expected by late November 2026. - Quotes from Dr. Jorge Santos da Silva: "The final Week 52 data from the VELA program confirm the strength of SLK across most, if not all, metrics that matter in HS: strong early efficacy, sustained and leading improvement over time, a consistent safety profile and great convenience in dosing." - Quotes from Prof. Kristian Reich: "What is particularly compelling in the final Week 52 dataset is how consistently the strong clinical efficacy of SLK is reflected in Patient-Reported Outcomes." Let's write this note. Let's state intent. I will write the finding for MoonLake's sonelokimab results.

Fantastic. Now let's update the existing findings. First, let's update `hhs-clinical-trials-reform-operation-trialblazer` using the new June 22, 2026 launch details of Operation Trailblazer. Let's make sure we preserve the prior information about the initiative while adding the new concrete details about the pilot program, draft guidance for relying on 1 trial, QSP draft guidance, etc. Let's read the current note `hhs-clinical-trials-reform-operation-trialblazer` first to see its exact content, using `read_notes` or just updating it. Oh, let's list the notes using `read_notes` first to find out what's in there, or we can just fetch the notes. Let's do a `read_notes` on the topic to see what the prior findings look like.

Let's read the current content of `hhs-clinical-trials-reform-operation-trialblazer`. Wait, we can fetch it if we want, or we can just read the notes. Is there a tool to read a specific note? No, but `read_notes` gives a preview. Let's do a search or fetch the note by searching for it, or since we are rewriting it, we can just write the complete updated note based on the new RAPS source. Let's see: the new RAPS source is incredibly detailed and contains everything we need. Wait, let's also read the note `amgen-tavneos-fda-scrutiny-withdrawal-dispute` to make sure we update it properly. Let's do a search on web or look at the preview. The preview says: "Amgen (NASDAQ: AMGN) is actively defending its oral complement C5a receptor inhibitor, Tavneos (avacopan), against a formal proposal by the FDA's Center for Drug Evaluation and Research..." Let's write the updated note for `hhs-clinical-trials-reform-operation-trialblazer`. Let's state intent. I will write the updated note for `hhs-clinical-trials-reform-operation-trialblazer`.

Now let's update the note `amgen-tavneos-fda-scrutiny-withdrawal-dispute`. Let's write the updated note with the latest information, including Amgen's engagement of the Duke Clinical Research Institute (DCRI) to perform a fully blinded re-adjudication of the ADVOCATE trial's primary endpoints, the scheduled June 29, 2026 data submission deadline, the European Medicines Agency (EMA) review over data integrity, and the 20 deaths reported in Japan by Kissei Pharmaceutical related to drug-induced liver injury (DILI) and vanishing bile duct syndrome (VBS). Let's state intent. I will write the updated note for `amgen-tavneos-fda-scrutiny-withdrawal-dispute`.

This is excellent! We have written three new findings and updated two existing findings based on newly surfaced, highly consequential science and health events from June 2026. Let's record the event for the ISS air leaks watch using `record_event`. Wait, let's look up the details of the watch `ISS Russian Zvezda module air leaks and repairs` (ID: `019ea447-7d90-733c-acee-2eb6c1313c78`). The watch is ongoing. Let's see: - `thread_id`: `019ea447-7d90-733c-acee-2eb6c1313c78` - `cycle_id`: Let's check our cycle ID. Wait, the cycle ID is in the user kickoff or we can leave it empty when no telemetry, but the prompt says: "Provide a short summary of what happened and the outcome vs what was expected. Set resolves=true if this watch is now done (a one_shot catalyst), false if it's an ongoing watch that should keep tracking." Wait, does the tool require a cycle ID? Yes, `cycle_id` is a required parameter. Let's find the cycle ID. Looking at the chat ID in the kickoff: `topic-019e92c9-9dac-7a47-a1f2-f8f4037c94f9-cycle-ea8df9cb-ca5f-4f1b-9efb-f23cf7216c44`. So the cycle ID is `ea8df9cb-ca5f-4f1b-9efb-f23cf7216c44`. Let's use this cycle ID. Let's call `record_event`.

Ah, the web search budget for this cycle is spent. That's perfectly fine because I have already gathered all the necessary details and successfully written/updated all the relevant notes and registered the event. Let's double-check if there are other watches we can update or resolve. Wait, let's look at the watch list: - `Amgen Tavneos FDA hearing submission and public docket close` (ID: `019ec855-5381-7936-a3b6-a40d207e679d`): This is a dated catalyst for June 29, 2026. Since the current date is June 24, 2026, the submission hasn't officially closed yet. However, we have updated the finding detailing Amgen's plan to submit the Duke re-analysis by June 29. We will leave this watch open so it can be resolved in the next cycle when the deadline passes and the actual submission is confirmed. - `MoonLake BLA submission for sonelokimab in Hidradenitis Suppurativa` (ID: `019ef183-efef-70f6-9f55-cbbd11c943bb`): This is a dated catalyst for September 30, 2026. It remains open. - `MoonLake Phase 3 IZAR-1 trial readout of sonelokimab in psoriatic arthritis` (ID: `019ef184-1ea4-72e1-a12e-ed934bbac64e`): This is a dated catalyst for mid-2026. It remains open. Let's do a quick check to see if we can write a note for the ISS air leaks. Wait, does the ISS air leaks have a note or should we write one? Let's check the list of notes we read earlier. The notes listed in `read_notes` were: - `moonlake-sonelokimab-phase3-vela-hidradenitis-suppurativa` - `pfizer-ibrance-fda-approval-hr-her2-breast-cancer` - `gilead-trodelvy-fda-approval-first-line-tnbc` - `sanofi-tzield-type1-diabetes` - `moderna-h5n1-mrna-vaccine-phase3-cepi-funding` - `hhs-clinical-trials-reform-operation-trialblazer` - `zynlonta-phase3-lotis5-dlbcl-safety-concerns` - `zepzelca-phase3-lagoon-sclc-failure` - `povetacicept-fda-bla-acceptance-iga-nephropathy` - `uniqure-amt-130-huntington-disease-bla-path` There is no existing note for the ISS Russian Zvezda module air leaks. Let's write a new note for the ISS Russian Zvezda module air leaks to track this highly consequential science/space event, as it is a major ongoing topic. Let's make the slug: `iss-russian-zvezda-module-air-leak-crisis`. Let's call `write_note`. Let's state intent. I will write a new finding note for the ISS Russian Zvezda module air leak crisis.

Excellent! We have successfully written four new finding notes and updated two existing finding notes. Let's review what we have accomplished this cycle: 1. **Gilead's Trodelvy broad FDA approval in first-line metastatic TNBC** (June 24, 2026) -> Written under a new slug: `gilead-trodelvy-fda-approval-first-line-tnbc`. 2. **Pfizer's Ibrance FDA expansion in HR+/HER2+ metastatic breast cancer maintenance** (June 24, 2026) -> Written under a new slug: `pfizer-ibrance-fda-approval-hr-her2-breast-cancer`. 3. **MoonLake's Sonelokimab Phase 3 VELA Week 52 Results in HS** (June 21, 2026) -> Written under a new slug: `moonlake-sonelokimab-phase3-vela-hidradenitis-suppurativa`. 4. **ISS Russian Zvezda Module Air Leak Crisis** (June 5-18, 2026) -> Written under a new slug: `iss-russian-zvezda-module-air-leak-crisis`. 5. **HHS and FDA Formally Launch "Operation Trailblazer"** (June 22, 2026) -> Updated existing slug: `hhs-clinical-trials-reform-operation-trialblazer`. 6. **Amgen Enlists Duke to Re-evaluate Tavneos Data** -> Updated existing slug: `amgen-tavneos-fda-scrutiny-withdrawal-dispute`. 7. **ISS Russian Zvezda module air leaks and repairs watch** -> Recorded a major event regarding the June 5 emergency shelter-in-place and Russia's subsequent decision to decommission the PrK vestibule. This is a highly productive and successful research cycle! I am ready to complete the cycle and call the `finish_cycle` tool. Let's state intent and call the tool.

I have completed this research cycle, capturing several highly consequential breakthroughs, approvals, trials, and crises in science, health, and space. ### Summary of Findings & Updates #### 1. Major Oncology Approvals (June 24, 2026) * **Gilead's Trodelvy Secures Broad FDA Approval in First-Line Metastatic TNBC (`gilead-trodelvy-fda-approval-first-line-tnbc`)**: Trodelvy (sacituzumab govitecan-hziy) obtained a major regulatory expansion for first-line triple-negative breast cancer (TNBC). It was approved as a monotherapy for patients who are not candidates for PD-1/PD-L1 inhibitors (Phase 3 **ASCENT-03** trial, demonstrating a 38% reduction in risk of progression or death) and in combination with Merck's **Keytruda** for PD-L1-positive patients (Phase 3 **ASCENT-04** / Keynote-D19 trial, demonstrating a 35% improvement in PFS). This ignites a direct market war with Daiichi Sankyo and AstraZeneca's recently approved Datroway. * **Pfizer's Ibrance Wins First FDA Expansion in Seven Years (`pfizer-ibrance-fda-approval-hr-her2-breast-cancer`)**: The FDA approved Ibrance (palbociclib) as a maintenance option in combination with anti-HER2 therapy (trastuzumab $\pm$ pertuzumab) and endocrine therapy for hormone receptor-positive, HER2-positive (HR+/HER2+) metastatic breast cancer. Backed by the Phase 3 **PATINA** trial—which showed a 24% reduced risk of disease progression or death and extended median PFS by 15.2 months—this approval gives Pfizer a unique foothold as the only CDK4/6 inhibitor indicated for HR+ metastatic disease regardless of HER2 status. #### 2. Clinical Trial Breakthroughs (June 21, 2026) * **MoonLake's Sonelokimab Achieves Outstanding Phase 3 HS Results (`moonlake-sonelokimab-phase3-vela-hidradenitis-suppurativa`)**: MoonLake announced final 52-week results from its registrational Phase 3 **VELA-1** and **VELA-2** trials in moderate-to-severe hidradenitis suppurativa (HS). Sonelokimab (SLK) achieved a potential best-in-disease profile, with **67.2%** of patients reaching HiSCR75, **33.1%** reaching HiSCR100, and **26.0%** achieving complete inflammatory remission (IHS4-100). Outstanding results were also reported in the adolescent VELA-TEEN trial. MoonLake is on track to submit its BLA by late September 2026 and expects a PDUFA date allocation by late November 2026. #### 3. Public Health and Policy Updates * **HHS and FDA Formally Launch "Operation Trailblazer" (`hhs-clinical-trials-reform-operation-trialblazer`)**: On June 22, 2026, HHS Secretary Robert F. Kennedy, Jr. and the FDA launched this sweeping clinical trial reform initiative to counter China’s R&D rise. It includes a pilot program for **Expedited IND filings** with rolling submissions, a revised draft guidance clarifying when developers can rely on **a single pivotal trial (instead of two)** with confirmatory evidence, and draft guidelines on utilizing Quantitative Systems Pharmacology (QSP) to accelerate first-in-human dose-selection. * **Amgen Enlists Duke to Re-evaluate Tavneos Data (`amgen-tavneos-fda-scrutiny-withdrawal-dispute`)**: In its ongoing market-withdrawal battle with the FDA over data integrity and safety (8 deaths and 76 cases of DILI/VBS in the U.S.), Amgen hired the **Duke Clinical Research Institute (DCRI)** to perform a fully blinded re-adjudication of the Phase 3 ADVOCATE trial's primary endpoints. Amgen plans to submit this critical re-analysis by **June 29, 2026**, when the FDA public docket closes. Meanwhile, global scrutiny has intensified, with Japan's Kissei Pharmaceutical reporting 20 deaths among Tavneos patients since 2022. #### 4. Space Exploration Crises * **ISS Russian Zvezda Module Air Leak Crisis (`iss-russian-zvezda-module-air-leak-crisis`)**: On June 5, 2026, a critical air leak in the Russian segment's PrK vestibule forced five NASA astronauts to take emergency shelter in the SpaceX Crew Dragon capsule while Russian cosmonauts performed emergency repairs. Following a standoff over a risky saw-cutting repair proposed by Roscosmos, Russia has informed NASA that it will throw in the towel on repairs and permanently decommission the PrK vestibule by sealing the hatch. This permanently cuts off access to a key Progress cargo docking port at the end of the Zvezda module. All findings have been thoroughly documented and saved in the living workspace database.